Detalhe da pesquisa
1.
Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
Cochrane Database Syst Rev
; 1: CD013167, 2022 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35005781
2.
A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors.
Invest New Drugs
; 38(6): 1815-1825, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32524319
3.
Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
Cochrane Database Syst Rev
; 1: CD012988, 2020 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31994181
4.
Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-α and progesterone receptor-b.
Br J Cancer
; 119(11): 1316-1325, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30410061
5.
Letter to the editor: re Lu et al.
Support Care Cancer
; 29(1): 1-2, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32417967
6.
Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report.
BMC Ophthalmol
; 14: 18, 2014 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-24564293
7.
Poor Muscle Status, Dietary Protein Intake, Exercise Levels, Quality of Life and Physical Function in Women with Metastatic Breast Cancer at Chemotherapy Commencement and during Follow-Up.
Curr Oncol
; 30(1): 688-703, 2023 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36661703
8.
Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia.
Asia Pac J Clin Oncol
; 18(3): 201-208, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33855786
9.
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy.
JNCI Cancer Spectr
; 4(1): pkz085, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32337496
10.
Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab.
Am Heart J
; 158(2): 294-301, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19619708
11.
Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE).
Clin Breast Cancer
; 19(3): 216-224, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30922805
12.
Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer.
Clin Breast Cancer
; 18(5): e1181-e1187, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29778788
13.
Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer.
Asia Pac J Clin Oncol
; 14 Suppl 4: 12-21, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30288929
14.
Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm.
Asia Pac J Clin Oncol
; 14 Suppl 4: 3-11, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30288930
15.
Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis.
Crit Rev Oncol Hematol
; 111: 66-80, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28259297
16.
Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
J Clin Pathol
; 70(11): 954-960, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28416639
17.
Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies.
Crit Rev Oncol Hematol
; 102: 37-46, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27105947
18.
Management of patients treated with pertuzumab in the Australian clinical practice setting.
Asia Pac J Clin Oncol
; 12 Suppl 2: 5-15, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27250913
19.
Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape.
Asia Pac J Clin Oncol
; 12 Suppl 1: 3-18, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27001208
20.
Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape.
Asia Pac J Clin Oncol
; 12 Suppl 1: 19-31, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27001209